Follow the Money: The Outlook for Outsourced Spending on Early Development Services
List Price: US $1,995
Delivery format: Electronic PDF delivery within one business day upon payment.
*This report is included at no extra cost for Strategic Advantage clients, and is accessible in the Trend Reports and Analyses section here.
Demand for development services to support Phase 1 and Phase 2 clinical trials is driving double-digit growth for CROs and CDMOs. Demand for clinical manufacturing services is actually outstripping industry capacity and leading to delays in getting clinical trial materials needed for studies.
According to the latest PharmSource Trend Report, Follow the Money: The Outlook for Outsourced Spending on Early Development Services, the driver of this early development activity has been the huge level of external funding flowing into emerging bio/pharma companies from venture capitalists and public markets. However, external funding for bio/pharma has always been a “boom or bust” proposition, and the likelihood that funding will be cut drastically always lurks on the horizon. This makes it difficult for CDMOs and CROs to pull the trigger on investments in new capacity.
Follow the Money: The Outlook for Outsourced Spending on Early Development Services examines the link between external funding sources and early drug development, and addresses the outlook for continued funding over the next two years.
Who should buy this report?
The 23-page report provides important insight that you won’t find in any other source. This report is required reading for:
- CDMOs and CROs: market trends, capital investment decision-making, strategic planning, performance benchmarking
- Bio/pharma: supplier performance benchmarking, market trends, competitive intelligence
- Private equity: investment targeting, portfolio company performance benchmarking
Published January 2017